Powered by HealthTechMovers.com
We added 1 stock to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
CTI BioPharma, CTIC
Summary: CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington.
- Last Price: 1.67
- Price Change: 0.06, 3.73%
- Yearly Gain: -52.51%
- Market Cap: 161.48M
- P/E Ratio: -1.8
Here are 3rd party ratings for CTIC:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 40% (152 out of 253)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Very High
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in CTIC or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CTIC before you decide to make any investment.
Click here for chart >>
Thanks for reading!